Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the... by Matt Wasserman, Maria Gabriela Palacios, Ana Gabriela Grajales, Michele Wilson, Cheryl McDade, Raymond Farkouh

Get full text

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands by Michele Wilson, Cheryl McDade, Anna Trisia Beby-Heijtel, Angela Waterval-Overbeek, Vishalini Sundaram, Johnna Perdrizet

Get full text

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia by Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat

Get full text

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom by Michele Wilson, Aaron Lucas, Diana Mendes, Andrew Vyse, Boglarka Mikudina, Carole Czudek, Gillian Frances Ellsbury, Johnna Perdrizet

Get full text

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada,... by Johnna Perdrizet, Emily K. Horn, Kyla Hayford, Lindsay Grant, Rachid Barry, Liping Huang, Cheryl McDade, Michele Wilson

Get full text

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico by Matthew Wasserman, Maria Gabriela Palacios, Ana Gabriela Grajales, F. Berenice Baez/Revueltas, Michele Wilson, Cheryl McDade, Raymond Farkouh

Get full text